CTNI-15. CLINICAL EFFICACY OF ONC201 IN NEWLY DIAGNOSED DIPG AND IN PREVIOUSLY IRRADIATED PEDIATRIC H3 K27M-MUTANT GLIOMAS

ONC201, an anti-cancer DRD2 antagonist and ClpP agonist, is in Phase II trials for adult H3 K27M-mutant diffuse midline gliomas. In adults, the recommended phase 2 dose (RP2D) of 625mg ONC201 once a week has been established as a biologically active dose that is well tolerated. Radiographic regressi...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Gardner, Sharon, Koschmann, Carl, Tarapore, Rohinton S, Allen, Jeffrey, Zaky, Wafik, Odia, Yazmin, Hall, Matthew, Daghistani, Doured, Khatib, Ziad, Aguilera, Dolly, MacDonald, Tobey, Fouladi, Maryam, McGovern, Susan, Mueller, Sabine, Kline, Cassie, Vitanza, Nicholas, Lu, Guangrong, Allen, Joshua, Khatua, Soumen
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2020
主題:
Clinical Trials: Non-Immunologic
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650473/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.182
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料